<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02794168</url>
  </required_header>
  <id_info>
    <org_study_id>VAS203/III/1/04</org_study_id>
    <nct_id>NCT02794168</nct_id>
  </id_info>
  <brief_title>Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury</brief_title>
  <acronym>NOSTRA-III</acronym>
  <official_title>Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury - (NOSTRA Phase III Trial): A Confirmatory, Placebo-controlled, Randomised, Double Blind, Multi-centre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vasopharm GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vasopharm GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of an infusion of Ronopterin (VAS203) on clinical outcome
      in patients with moderate and severe traumatic brain injury. Half of the participants will
      receive Ronopterin (VAS203), while the other half will receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe and moderate traumatic brain injury (TBI) constitutes a major health problem. TBI is
      the leading cause of death and disability among young adults in developed countries, and the
      incidence in the elderly population is increasing.

      Neurological damage after TBI is caused not only by the accident itself, but evolves
      afterwards. The posttraumatic secondary injury includes - among others - inflammation and
      oedema formation with subsequent increase of intracranial pressure. A key molecule in these
      processes is the gas nitric oxide, which is produced in excess during neuroinflammation.

      Ronopterin (VAS203) is an inhibitor of nitric oxide synthase. Ronopterin reduces excess
      nitric oxide production and subsequent secondary injury.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>extended Glasgow Outcome Scale</measure>
    <time_frame>6 months</time_frame>
    <description>clinical outcome questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life after brain injury (QOLIBRI)</measure>
    <time_frame>6 months</time_frame>
    <description>clinical outcome questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOLIBRI overall scale</measure>
    <time_frame>6 months</time_frame>
    <description>clinical outcome questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>extended Glasgow Outcome Scale</measure>
    <time_frame>3 months</time_frame>
    <description>clinical outcome questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOLIBRI overall scale</measure>
    <time_frame>3 months</time_frame>
    <description>clinical outcome questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy Intensity Level</measure>
    <time_frame>14 days</time_frame>
    <description>Daily recording of score for therapeutic measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of decompressive craniectomies</measure>
    <time_frame>14 days</time_frame>
    <description>Number of decompressive craniotomies on both hemispheres</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>14 days</time_frame>
    <description>Number of adverse events related to treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Intracranial Pressure (ICP) and Cerebral Perfusion Pressure (CPP)</measure>
    <time_frame>5 days</time_frame>
    <description>Hourly recording of ICP and CPP</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal function</measure>
    <time_frame>14 days</time_frame>
    <description>Number of patients exhibiting acute kidney injury according Acute Kidney Injury Network criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>6 Months</time_frame>
    <description>Mortality 6 months after traumatic brain injury</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>VAS203 (Ronopterin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of 17 mg/kg VAS203 over 48 hours, daily dose 8.5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous infusion of physiological saline over 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAS203</intervention_name>
    <description>Treatment</description>
    <arm_group_label>VAS203 (Ronopterin)</arm_group_label>
    <other_name>Ronopterin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent from patient's legal guardian or legal representative or
             deferred consent procedure, according to local requirements

          2. 18 - 60 years of age, inclusive

          3. Expected to survive more than 24 hours after admission

          4. Traumatic Brain Injury (TBI) within the last 18 hours (infusion must not start earlier
             than 6 hours after the injury)

          5. TBI with Glasgow Coma Score (GCS) ≥ 3 requiring intracranial pressure (ICP) monitoring
             according to the assessment of the treating physician.

          6. Catheter placement (intraventricular or intraparenchymal, only) for monitoring and
             management of increased ICP

          7. Systolic blood pressure ≥ 100 mmHg

          8. Females of child-bearing potential must have a negative pregnancy test

        Exclusion Criteria:

          1. Penetrating head injury (e.g. missile, stab wound)

          2. Concurrent, but not pre-existing, spinal cord injury

          3. Bilateral fixed and dilated pupil (&gt; 4 mm)

          4. Cardiopulmonary resuscitation performed post injury, or extracranial injuries causing
             continuing bleeding likely to require multiple transfusions (&gt; 4 units red blood
             cells)

          5. Coma due to an exclusive epidural hematoma (lucid interval and absence of structural
             brain damage on CT scan)

          6. Coma suspected to be primarily due to other causes than head injury (e.g. drug
             overdose intoxication, drowning/near drowning)

          7. Known or CT scan evidence of pre-existing major cerebral damage

          8. Patients who cannot be monitored with regard to their recovery (eGOS-I and QOLIBRI)

          9. Patients and relatives of patients who don´t understand/speak Spanish, or English, or
             French, or German

         10. Decompressive craniectomy, planned prior to randomisation

         11. Polytraumatic patients with Injury Severity Score non-head &gt; 18

         12. Rhabdomyolysis with Creatine Kinase &gt; 5000 IU/L

         13. Injuries to ascending aorta and/or carotid arteries and vertebral arteries

         14. Serum creatinine values &gt; 1.2 mg/dL (106 µmol/L) (women), or &gt; 1.5 mg/dL (133 µmol/L)
             (men)

         15. Estimated glomerular filtration rate (eGFR) &lt; 60 mL/min as calculated by Chronic
             Kidney Disease Epidemiology Collaboration Formula

         16. BMI &lt; 18.5 kg/m2 and &gt; 40 kg/m2, Body weight &gt; 110 kg

         17. Any severe concomitant condition (cancer; hematologic, renal, hepatic, coronary
             disease; major psychiatric disorder; alcohol or drug abuse), that can be ascertained
             at admission

         18. Known to have received an experimental drug within 4 weeks prior to current injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erich Schmutzhard, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Innsbruck</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reinhard Schinzel, PhD</last_name>
    <phone>+49 931 359099</phone>
    <phone_ext>115</phone_ext>
    <email>schinzel@vasopharm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank Tegtmeier, PhD</last_name>
    <phone>+49 931 359099</phone>
    <phone_ext>230</phone_ext>
    <email>tegtmeier@vasopharm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinik für Neurochirurgie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mokry, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurologie und Neurochirurgie Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronny Beer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Allgemeine Anästhesie und Intensivmedizin AKH Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Willschke, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pellegrin Service de réanimation traumatologique et chirurgicale</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Cottenceau, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell Chabanne, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Wertheimer,</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Dailler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pôle Anesthésie Réanimation Douleur Urgence</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves Lefrant, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIA Sainte-Anne Boulevard Sainte-Anne</name>
      <address>
        <city>Toulon</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ambroise Montcriol, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Wolf, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Berufsgenossenschaftliche Kliniken Bergmannsheil Klinik für Neurochirurgie</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Martinez, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Celle Neurotraumatologie</name>
      <address>
        <city>Celle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eckhard Rickels, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf Neurochirurgische Klinik</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Beseoglu, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurochirurgie Universität Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Senft, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen Klinik für Neurochirurgie</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothea Mielke, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Berufsgenossenschaftliche Kliniken Bergmannstrost Halle Klinik für Neurochirurgie</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Meisel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Neurochirurgie</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Czorlich, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover Klinik für Neurochirurgie</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Lang, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurochirurgische Universitätsklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Unterberg, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlands</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Szczygielski, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena Klinik und Poliklinik für Neurochirurgie</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Walter, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Klinik für Neurochirurgie</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Synowitz, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig Klinik und Poliklinik für Neurochirurgie</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Meixensberger, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Holling, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg Klinik und Poliklinik für Neurochirurgie</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf-Ingo Ernestus, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital Department of Neurosurgery</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Sahuquillo, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic University of Barcelona Surgical Intensive Care Unit</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Zavala, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario</name>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perez Ana</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Son Espases University Hospital</name>
      <address>
        <city>Palma</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Ibanez, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Belli, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHS Lothian University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Andrew, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christos Tolias, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospital Division of Clinical Neurosciences</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diederik Bulters, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Stover JF, Belli A, Boret H, Bulters D, Sahuquillo J, Schmutzhard E, Zavala E, Ungerstedt U, Schinzel R, Tegtmeier F; NOSTRA Investigators. Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606. doi: 10.1089/neu.2014.3344. Epub 2014 Jul 28.</citation>
    <PMID>24831445</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

